Benzinga | Feb 23, 2021 11:25AM EST

HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $19

HC Wainwright & Co. maintains BioLine Rx (NASDAQ:BLRX) with a Buy and lowers the price target from $22 to $19.